Production of a compound comprising n-acetylglucosamine-beta-1,6-galactose-beta-1,4-glucose or n-acetylglucosamine-beta-1,6-galactose-beta-1,4-n-acetylglucosamine

The method of using UDP-GlcNAc and beta-1,6-N-acetylglucosaminyltransferase to form beta-1,6-glycosidic linkages addresses the challenge of producing N-acetylglucosamine-beta-1,6-galactose-beta-1,4-Zi-Z2 compounds efficiently, achieving high yields suitable for industrial use.

WO2026115116A2 Publication Date: 2026-06-04INBIOSE NV
9 Cites 0 Cited by

Patent Information

Application Number
PCT/EP2025/084717
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2024-11-29
Filing Date
2025-11-28
Publication Date
2026-06-04

AI Technical Summary

Technical Problem

The challenge lies in efficiently producing a compound comprising N-acetylglucosamine-beta-1,6-galactose-beta-1,4-Zi-Z2, where Zi is glucose or N-acetylglucosamine, and Z2 is absent or a saccharide, particularly due to the difficulty in introducing a beta-1,6-branch on growing saccharides or saccharides bound to peptides, proteins, or lipids.

Method used

A method involving the use of UDP-N-acetylglucosamine (UDP-GlcNAc) and a beta-1,6-N-acetylglucosaminyltransferase to transfer N-acetylglucosamine to a galactose-beta-1,4-Zi-Z2 acceptor, forming a beta-1,6-glycosidic linkage, optionally with additional glycosyltransferases, in controlled conditions such as temperature and pH, to produce the desired compound.

Benefits of technology

This method enables the production of the compound in high yields, reaching up to 100 g/L, suitable for industrial applications, using cells like Escherichia coli expressing the beta-1,6-N-acetylglucosaminyltransferase.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention is in the technical field of synthetic biology, metabolic engineering and cell cultivation. The present invention describes methods for the production of a compound comprising N-acetylglucosamine-beta-1,6-galactose-beta-1,4-Z1-Z2-R, wherein Z1 is glucose or N-acetylglucosamine (GlcNAc), wherein Z2 is absent or is a saccharide, and wherein R is absent or is selected from the list consisting of a peptide, a protein and a lipid. The invention further describes a cell that is capable to produce said compound.
Need to check novelty before this filing date? Find Prior Art